AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
For the full year, sales was SEK 34.68 million compared to SEK 44.65 million a year ago. Net loss was SEK 2.22 million compared to net income of SEK 5.16 million a year ago. Basic loss per share from continuing operations was SEK 0.04 compared to basic earnings per share from continuing operations of SEK 0.08 a year ago.